Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1996;28:98-103

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dieguez-Lucena, J. L.
Right arrow Articles by Reyes-Engel, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dieguez-Lucena, J. L.
Right arrow Articles by Reyes-Engel, A.

(Hypertension. 1996;28:98-103.)
© 1996 American Heart Association, Inc.


Articles

Angiotensin I–Converting Enzyme Genotypes and Angiotensin II Receptors

Response to Therapy

Jose L. Dieguez-Lucena; Pedro Aranda-Lara; Maximiliano Ruiz-Galdon; Javier Garcia-Villanova; Miguel Morell-Ocana; Armando Reyes-Engel

Departamento Bioquimica y Biologia Molecular, Facultad de Medicina, Universidad de Malaga, and Hospital Regional Carlos Haya (P.A.-L.), Malaga, Spain.

In the present study, we studied angiotensin II type 1 (AT1) and type 2 (AT2) receptor messengers by quantitative reverse transcriptase–polymerase chain reaction. We examined peripheral blood mononuclear cells from 30 healthy subjects and 50 subjects with primary hypertension, in whom angiotensin I–converting enzyme genotype was determined, before and after 15 days of treatment with different antihypertensive drugs. The medication included a calcium channel antagonist, an angiotensin I–converting enzyme inhibitor, and a ß1-blocker. We also studied the relationship between AT1 receptor gene expression and biochemical parameters of the renin-angiotensin system. AT1 receptor messenger levels were positively correlated with plasma renin activity in both normotensive and untreated hypertensive subjects. Increases of this messenger and plasma angiotensin II levels were correlated with the D allele in the same individuals. AT1 receptor messenger levels decreased significantly with angiotensin I–converting enzyme inhibitor treatment in subjects with the DD genotype, and a significant decrease was observed in subjects with the II and ID genotypes treated with a calcium antagonist. No changes were observed in mRNA with the ß1-blocker. We conclude that the AT2 receptor is not expressed in peripheral leukocytes and that AT1 receptor messenger levels vary in relation to angiotensin I–converting enzyme genotype and pharmacological treatment. These results suggest that angiotensin I–converting enzyme genotype may be an important factor when deciding on antihypertensive therapy in individuals with primary hypertension.


Key Words: receptors, angiotensin II • angiotensin-converting enzyme • antihypertensive therapy • genotype • polymerase chain reaction • RNA




This article has been cited by other articles:


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
H. J Milionis, M. S Kostapanos, K. Vakalis, I. Theodorou, I. Bouba, R. Kalaitzidis, I. Georgiou, M. S Elisaf, and K. C Siamopoulos
Impact of renin-angiotensin-aldosterone system genes on the treatment response of patients with hypertension and metabolic syndrome
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 181 - 189.
[Abstract] [PDF]


Home page
Exp PhysiolHome page
B. Baudin
Polymorphism in angiotensin II receptor genes and hypertension
Exp Physiol, May 1, 2005; 90(3): 277 - 282.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Jones, S. S. Dhamrait, J. R. Payne, E. Hawe, P. Li, I. S. Toor, L. Luong, P. T.E. Wootton, G. J. Miller, S. E. Humphries, et al.
Genetic Variants of Angiotensin II Receptors and Cardiovascular Risk in Hypertension
Hypertension, October 1, 2003; 42(4): 500 - 506.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
X. Li, Y. Du, Y. Du, and X. Huang
Correlation of Angiotensin-Converting Enzyme Gene Polymorphism with Effect of Antihypertensive Therapy by Angiotensin-Converting Enzyme Inhibitor
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 25 - 30.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. L. Anderson, J. F. Carlquist, B. D. Home, and J. B. Muhlestein
Cardiovascular Pharmacogenomics: Current Status, Future Prospects
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 71 - 83.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
M. M. Redfield, R. J. Rodeheffer, S. J. Jacobsen, D. W. Mahoney, K. R. Bailey, and J. C. Burnett Jr
Plasma brain natriuretic peptide concentration: impact of age and gender
J. Am. Coll. Cardiol., September 4, 2002; 40(5): 976 - 982.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. Wang, A. Zagariya, O. Ibarra-Sunga, C. Gidea, E. Ang, S. Deshmukh, G. Chaudhary, J. Baraboutis, G. Filippatos, and B. D. Uhal
Angiotensin II induces apoptosis in human and rat alveolar epithelial cells
Am J Physiol Lung Cell Mol Physiol, May 1, 1999; 276(5): L885 - L889.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
G. I. Rice, C. A. Foy, and P. J. Grant
Angiotensin converting enzyme and angiotensin II type 1-receptor gene polymorphisms and risk of ischaemic heart disease
Cardiovasc Res, March 1, 1999; 41(3): 746 - 753.
[Abstract] [Full Text] [PDF]